ScoreWhy is Bliss GVS Pharma Ltd ?
1
The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 9.94% and Operating profit at 7.87% over the last 5 years
3
Positive results in Mar 26
- PAT(Q) At Rs 35.56 cr has Grown at 128.8%
- ROCE(HY) Highest at 16.80%
- DEBT-EQUITY RATIO(HY) Lowest at 0.02 times
4
With ROE of 11, it has a Very Expensive valuation with a 3.9 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 195.61%, its profits have risen by 55% ; the PEG ratio of the company is 0.7
5
Falling Participation by Institutional Investors
- Institutional investors have decreased their stake by -4.84% over the previous quarter and collectively hold 15.49% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
6
Market Beating performance in long term as well as near term
- Along with generating 195.61% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Bliss GVS Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Bliss GVS Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Bliss GVS Pharma
195.61%
3.25
60.28%
Sensex
-7.55%
-0.58
13.06%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.94%
EBIT Growth (5y)
7.87%
EBIT to Interest (avg)
14.32
Debt to EBITDA (avg)
0.68
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
0.74
Tax Ratio
28.94%
Dividend Payout Ratio
6.25%
Pledged Shares
0
Institutional Holding
15.49%
ROCE (avg)
12.39%
ROE (avg)
9.73%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
34
Price to Book Value
3.90
EV to EBIT
34.54
EV to EBITDA
27.49
EV to Capital Employed
4.31
EV to Sales
4.86
PEG Ratio
0.66
Dividend Yield
0.23%
ROCE (Latest)
12.48%
ROE (Latest)
10.95%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
PAT(Q)
At Rs 35.56 cr has Grown at 128.8%
ROCE(HY)
Highest at 16.80%
DEBT-EQUITY RATIO(HY)
Lowest at 0.02 times
NET SALES(Q)
Highest at Rs 256.99 cr
PBDIT(Q)
Highest at Rs 44.44 cr.
PBT LESS OI(Q)
Highest at Rs 33.76 cr.
-4What is not working for the Company
INTEREST(Q)
At Rs 2.01 cr has Grown at 34.90%
Loading Valuation Snapshot...
Here's what is working for Bliss GVS Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 33.76 cr has Grown at 196.92%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 35.56 cr has Grown at 128.8%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 0.02 times and Fallen
each half year in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales - Quarterly
Highest at Rs 256.99 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 256.99 cr has Grown at 29.80%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 44.44 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 33.76 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Here's what is not working for Bliss GVS Pharma
Interest - Quarterly
At Rs 2.01 cr has Grown at 34.90%
Quarter on Quarter (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
